APA (7th ed.) Citation

T, Z., S, P., SS, T., F, H., K, T., W, S., . . . M, B. (2022). Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF-07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS-CoV-2, in Healthy Adult Participants. Clinical pharmacology in drug development, 11(12), 1382. https://doi.org/10.1002/cpdd.1174

Chicago Style (17th ed.) Citation

T, Zhu, et al. "Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF-07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS-CoV-2, in Healthy Adult Participants." Clinical Pharmacology in Drug Development 11, no. 12 (2022): 1382. https://doi.org/10.1002/cpdd.1174.

MLA (9th ed.) Citation

T, Zhu, et al. "Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF-07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS-CoV-2, in Healthy Adult Participants." Clinical Pharmacology in Drug Development, vol. 11, no. 12, 2022, p. 1382, https://doi.org/10.1002/cpdd.1174.